|
|
Office Locations:
|
16 Laurel Ave, Suite 150
Wellesley, MA 02481
Phone: 617-252-3443
Fax: 617-621-7993
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
The BioVentures Investors Group provides early-stage venture capital financing to enterprises in the healthcare industry. The firm's investments are concentrated in four areas: drug development, genomics, medical devices, and medical software. The three General Partners of the firm have all been CEOs of companies active in the biotech industry and have 62 years of combined experience. BioVentures currently manages three funds with over $133 million under management. Investments in individual companies typically range from $10 to $25 million dollars, with the expectation that a monetizing opportunity will be reached in less than five years with a total capital requirement of $15 million to $100 million. Although the firm focuses primarily on businesses that have a management team in place and have data from initial research and development to support claims, it will consider seed-stage investments.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
